Goldman Sachs
PHIO icon

Goldman Sachs’s Phio Pharmaceuticals PHIO Stock Holding History

Goldman Sachs’s Portfolio PHIO Stock Details PHIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-176
Closed -$43K – 6447
2021
Q2 		$43K Buy
+176
New +$43.4K ﹤0.01% 6085
2017
Q4 		– Hold
0
– -$9K – 6572
2017
Q3 		– Hold
0
– – – 6539
2017
Q1 		– Sell
-1
Closed -$41K – 6941
2016
Q4 		$41K Buy
+1
New +$78.2K ﹤0.01% 6443
2016
Q2 		– Hold
0
– -$5K – 7189
2016
Q1 		– Hold
0
– – – 6974
2015
Q4 		– Hold
0
– – – 7033
2015
Q3 		– Hold
0
– – – 7189
2015
Q2 		– Hold
0
– – – 7132
2015
Q1 		– Hold
0
– – – 6908
2014
Q4 		– Hold
0
– – – 6861
2014
Q2 		– Hold
0
– -$45K – 7107
2014
Q1 		– Hold
0
– – – 6583

Other funds holding PHIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs's PHIO Position: Q3 2021 in Review

Goldman Sachs sold out of Phio Pharmaceuticals (PHIO) in Q3 2021, closing a stake of 176 shares — an estimated $43K sold.

Goldman Sachs first reported a position in PHIO in Q4 2016 and held it in 2 quarters. The position peaked at $43K in Q2 2021. 15 funds tracked by Wall St. Rank hold PHIO as of Q3 2021.

  • Goldman Sachs reported no remaining Phio Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Goldman Sachs sold 176 Phio Pharmaceuticals shares in Q3 2021, an estimated $43K.
  • Goldman Sachs first reported a position in Phio Pharmaceuticals in Q4 2016 and held it in 2 quarters.
  • Goldman Sachs's Phio Pharmaceuticals position peaked at $43K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q3 2021.

Based on Goldman Sachs's 13F filing for Q3 2021, filed 10 Nov 2021.